Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated to v3.4.2 and the prior funding/operating-status notice was removed; these are site-wide housekeeping changes rather than updates to study details.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the system revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded: Show glossary toggle; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0. Deleted: Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page, with no evident changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedThe Locations section is reorganized into a consolidated 'Locations' block with added provinces (Beijing Municipality, Hebei, Heilongjiang, Hunan, Jilin, Shanxi, Sichuan), replacing the former province-specific location headings. The revision version updated from v3.3.2 to v3.3.3.SummaryDifference0.8%

- Check92 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. This update appears to be a metadata change with no impact on study details.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.